Investment analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, Cantor Fitzgerald increased their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st.
View Our Latest Report on Vanda Pharmaceuticals
Vanda Pharmaceuticals Stock Performance
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The firm had revenue of $50.47 million for the quarter. As a group, equities analysts forecast that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.
Institutional Trading of Vanda Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP raised its holdings in Vanda Pharmaceuticals by 39.8% during the 4th quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 161,737 shares during the last quarter. Sei Investments Co. raised its position in shares of Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after acquiring an additional 147,066 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at about $1,158,000. Acadian Asset Management LLC grew its stake in Vanda Pharmaceuticals by 4.7% during the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after purchasing an additional 107,203 shares during the period. Finally, Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals in the second quarter worth approximately $1,090,000. 88.14% of the stock is currently owned by institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Recommended Stories
- Five stocks we like better than Vanda Pharmaceuticals
- Stock Average Calculator
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Most Effectively Use the MarketBeat Earnings Screener
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.